Literature DB >> 16635021

Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade.

Nicholas M Radio1, John S Doctor, Paula A Witt-Enderby.   

Abstract

The goals of this study were to determine (a) if melatonin enhances human adult mesenchymal stem cell (hAMSC) differentiation into osteoblasts as assessed by measuring alkaline phosphatase (ALP) enzyme activity, and (b) identify potential signal transduction pathways that mediate this process. ALP activity significantly increased in hAMSCs following a 10-day incubation in osteogenic medium, relative to hAMSCs incubated in basal growth medium alone. Melatonin (50 nm), added in combination with the osteogenic medium, significantly increased ALP activity relative to osteogenic medium alone. Co-exposure of hAMSCs to osteogenic medium supplemented with melatonin and either pertussis toxin or the melatonin receptor antagonists, luzindole or 4P-PDOT (MT2 receptor selective), inhibited the melatonin-induced increase in ALP activity, indicating the involvement of melatonin receptors, in particular, MT2 receptors. Assessment of melatonin receptor function following exposure to osteogenic medium containing either vehicle or melatonin produced dichotomous results. That is, if the differentiation of hAMSCs into an osteoblast was induced by osteogenic medium alone, then 2-[125I]-iodomelatonin binding and melatonin receptor function increased. However, examination of melatonin receptor function following chronic melatonin exposure, an exposure that resulted in a 50% enhancement in ALP activity, revealed that these receptors were desensitized. This was reflected by a complete loss in specific 2-[125I]-iodomelatonin binding as well as melatonin efficacy to inhibit forskolin-induced cAMP accumulation. Further characterization of the mechanisms underlying melatonin's effects on these differentiation processes revealed that MEK (1/2) and ERK (1/2), epidermal growth factor receptors, metalloproteinase and clathrin-mediated endocytosis were essential while PKA was not. Our results are consistent with a role for melatonin in osteoblast differentiation. If so, then, the decrease in plasma melatonin levels observed in humans during late adulthood may further enhance susceptibility to osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635021     DOI: 10.1111/j.1600-079X.2006.00318.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  54 in total

1.  Melatonin release by exocytosis in the rat parotid gland.

Authors:  Michela Isola; Jörgen Ekström; Raffaella Isola; Francesco Loy
Journal:  J Anat       Date:  2018-12-10       Impact factor: 2.610

2.  Melatonin reverses H2 O2 -induced premature senescence in mesenchymal stem cells via the SIRT1-dependent pathway.

Authors:  Long Zhou; Xi Chen; Tao Liu; Yihong Gong; Sijin Chen; Guoqing Pan; Wenguo Cui; Zong-Ping Luo; Ming Pei; Huilin Yang; Fan He
Journal:  J Pineal Res       Date:  2015-07-07       Impact factor: 13.007

3.  A novel combination treatment to stimulate bone healing and regeneration under hypoxic conditions: photobiomodulation and melatonin.

Authors:  Jang-Ho Son; Bong-Soo Park; In-Ryoung Kim; Iel-Yong Sung; Yeong-Cheol Cho; Jung-Soo Kim; Yong-Deok Kim
Journal:  Lasers Med Sci       Date:  2017-01-13       Impact factor: 3.161

4.  Comparison of melatonin with growth factors in promoting precursor cells proliferation in adult mouse subventricular zone.

Authors:  Areechun Sotthibundhu; Kasima Ekthuwapranee; Piyarat Govitrapong
Journal:  EXCLI J       Date:  2016-12-21       Impact factor: 4.068

5.  Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis.

Authors:  Sifat Maria; Rebekah M Samsonraj; Fahima Munmun; Jessica Glas; Maria Silvestros; Mary P Kotlarczyk; Ryan Rylands; Amel Dudakovic; Andre J van Wijnen; Larry T Enderby; Holly Lassila; Bala Dodda; Vicki L Davis; Judy Balk; Matt Burow; Bruce A Bunnell; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2018-01-17       Impact factor: 13.007

6.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

Review 7.  Melatonin and the skeleton.

Authors:  A K Amstrup; T Sikjaer; L Mosekilde; L Rejnmark
Journal:  Osteoporos Int       Date:  2013-05-29       Impact factor: 4.507

8.  Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors.

Authors:  Marta Imbesi; Tolga Uz; Svetlana Dzitoyeva; Pietro Giusti; Hari Manev
Journal:  Brain Res       Date:  2008-06-28       Impact factor: 3.252

9.  Melatonin attenuated adipogenesis through reduction of the CCAAT/enhancer binding protein beta by regulating the glycogen synthase 3 beta in human mesenchymal stem cells.

Authors:  Yun-Hee Rhee; Jin-Chul Ahn
Journal:  J Physiol Biochem       Date:  2016-01-21       Impact factor: 4.158

Review 10.  Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives.

Authors:  Stephen G Grant; Melissa A Melan; Jean J Latimer; Paula A Witt-Enderby
Journal:  Expert Rev Mol Med       Date:  2009-02-05       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.